Cargando…
Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer
This phase II study evaluated the response rate and tolerability of gemcitabine–oxaliplatin chemotherapy in non-small-cell lung cancer (NSCLC) patients. Chemonaive patients with stage IIIB or IV NSCLC received gemcitabine 1000 mg m(−2) on days 1 and 8, followed by oxaliplatin 130 mg m(−2) on day 1....
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361475/ https://www.ncbi.nlm.nih.gov/pubmed/15956971 http://dx.doi.org/10.1038/sj.bjc.6602667 |
_version_ | 1782153220348444672 |
---|---|
author | Cappuzzo, F Novello, S De Marinis, F Franciosi, V Maur, M Ceribelli, A Lorusso, V Barbieri, F Castaldini, L Crucitta, E Marini, L Bartolini, S Scagliotti, G V Crinò, L |
author_facet | Cappuzzo, F Novello, S De Marinis, F Franciosi, V Maur, M Ceribelli, A Lorusso, V Barbieri, F Castaldini, L Crucitta, E Marini, L Bartolini, S Scagliotti, G V Crinò, L |
author_sort | Cappuzzo, F |
collection | PubMed |
description | This phase II study evaluated the response rate and tolerability of gemcitabine–oxaliplatin chemotherapy in non-small-cell lung cancer (NSCLC) patients. Chemonaive patients with stage IIIB or IV NSCLC received gemcitabine 1000 mg m(−2) on days 1 and 8, followed by oxaliplatin 130 mg m(−2) on day 1. Cycles were repeated every 21 days for up to six cycles. From February 2002 to May 2004, 60 patients were enrolled into the study in seven Italian institutions. We observed one complete response (1.7%) and 14 partial responses (23.3%), for an overall response rate of 25.0% (95% confidence interval, 14.7–37.9%). The median duration of response was 5.9 months (range 1.5–17.1 months). With a median follow-up of 6.7 months, median time to progressive disease and overall survival were 2.7 (range 1.9–3.4 months) and 7.3 months (range 7.2–8.6 months), respectively. The main grade 3–4 haematological toxicities were transient neutropenia in 11.7% and thrombocytopenia in 8.3% of the patients. Nausea/vomiting was the main grade 3–4 nonhaematological toxicity, occurring in 10.0% of the patients. Two (3.3%) patients developed grade 3 neurotoxicity. Our results show that gemcitabine–oxaliplatin chemotherapy is active and well tolerated in patients with advanced NSCLC, deserving further study, especially for patients not eligible to receive cisplatin. |
format | Text |
id | pubmed-2361475 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2005 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23614752009-09-10 Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer Cappuzzo, F Novello, S De Marinis, F Franciosi, V Maur, M Ceribelli, A Lorusso, V Barbieri, F Castaldini, L Crucitta, E Marini, L Bartolini, S Scagliotti, G V Crinò, L Br J Cancer Clinical Study This phase II study evaluated the response rate and tolerability of gemcitabine–oxaliplatin chemotherapy in non-small-cell lung cancer (NSCLC) patients. Chemonaive patients with stage IIIB or IV NSCLC received gemcitabine 1000 mg m(−2) on days 1 and 8, followed by oxaliplatin 130 mg m(−2) on day 1. Cycles were repeated every 21 days for up to six cycles. From February 2002 to May 2004, 60 patients were enrolled into the study in seven Italian institutions. We observed one complete response (1.7%) and 14 partial responses (23.3%), for an overall response rate of 25.0% (95% confidence interval, 14.7–37.9%). The median duration of response was 5.9 months (range 1.5–17.1 months). With a median follow-up of 6.7 months, median time to progressive disease and overall survival were 2.7 (range 1.9–3.4 months) and 7.3 months (range 7.2–8.6 months), respectively. The main grade 3–4 haematological toxicities were transient neutropenia in 11.7% and thrombocytopenia in 8.3% of the patients. Nausea/vomiting was the main grade 3–4 nonhaematological toxicity, occurring in 10.0% of the patients. Two (3.3%) patients developed grade 3 neurotoxicity. Our results show that gemcitabine–oxaliplatin chemotherapy is active and well tolerated in patients with advanced NSCLC, deserving further study, especially for patients not eligible to receive cisplatin. Nature Publishing Group 2005-07-11 2005-06-14 /pmc/articles/PMC2361475/ /pubmed/15956971 http://dx.doi.org/10.1038/sj.bjc.6602667 Text en Copyright © 2005 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Study Cappuzzo, F Novello, S De Marinis, F Franciosi, V Maur, M Ceribelli, A Lorusso, V Barbieri, F Castaldini, L Crucitta, E Marini, L Bartolini, S Scagliotti, G V Crinò, L Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer |
title | Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer |
title_full | Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer |
title_fullStr | Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer |
title_full_unstemmed | Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer |
title_short | Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer |
title_sort | phase ii study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361475/ https://www.ncbi.nlm.nih.gov/pubmed/15956971 http://dx.doi.org/10.1038/sj.bjc.6602667 |
work_keys_str_mv | AT cappuzzof phaseiistudyofgemcitabineplusoxaliplatinasfirstlinechemotherapyforadvancednonsmallcelllungcancer AT novellos phaseiistudyofgemcitabineplusoxaliplatinasfirstlinechemotherapyforadvancednonsmallcelllungcancer AT demarinisf phaseiistudyofgemcitabineplusoxaliplatinasfirstlinechemotherapyforadvancednonsmallcelllungcancer AT franciosiv phaseiistudyofgemcitabineplusoxaliplatinasfirstlinechemotherapyforadvancednonsmallcelllungcancer AT maurm phaseiistudyofgemcitabineplusoxaliplatinasfirstlinechemotherapyforadvancednonsmallcelllungcancer AT ceribellia phaseiistudyofgemcitabineplusoxaliplatinasfirstlinechemotherapyforadvancednonsmallcelllungcancer AT lorussov phaseiistudyofgemcitabineplusoxaliplatinasfirstlinechemotherapyforadvancednonsmallcelllungcancer AT barbierif phaseiistudyofgemcitabineplusoxaliplatinasfirstlinechemotherapyforadvancednonsmallcelllungcancer AT castaldinil phaseiistudyofgemcitabineplusoxaliplatinasfirstlinechemotherapyforadvancednonsmallcelllungcancer AT crucittae phaseiistudyofgemcitabineplusoxaliplatinasfirstlinechemotherapyforadvancednonsmallcelllungcancer AT marinil phaseiistudyofgemcitabineplusoxaliplatinasfirstlinechemotherapyforadvancednonsmallcelllungcancer AT bartolinis phaseiistudyofgemcitabineplusoxaliplatinasfirstlinechemotherapyforadvancednonsmallcelllungcancer AT scagliottigv phaseiistudyofgemcitabineplusoxaliplatinasfirstlinechemotherapyforadvancednonsmallcelllungcancer AT crinol phaseiistudyofgemcitabineplusoxaliplatinasfirstlinechemotherapyforadvancednonsmallcelllungcancer |